|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001554,
umls-concept:C0003250,
umls-concept:C0030705,
umls-concept:C0034897,
umls-concept:C0036525,
umls-concept:C0085264,
umls-concept:C0086418,
umls-concept:C0205262,
umls-concept:C0205390,
umls-concept:C0303611,
umls-concept:C0814225,
umls-concept:C1096776,
umls-concept:C1273870,
umls-concept:C1522484,
umls-concept:C1527249
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
1998-9-8
|
|
pubmed:abstractText |
The study contained herein was undertaken to evaluate the accuracy of radiolabeled human monoclonal antibody, 88BV59H21-2V67-66 (88BV59 or HumaSPECT-Tc), in predicting disease resectability in presurgical subjects with recurrent, metastatic, or occult colorectal carcinoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0012-3706
|
|
pubmed:author |
pubmed-author:BaumRR,
pubmed-author:BoltonJJ,
pubmed-author:ChetanneauAA,
pubmed-author:FischmanA JAJ,
pubmed-author:GoroffD KDK,
pubmed-author:HannaM GMGJr,
pubmed-author:HooverH CHCJr,
pubmed-author:KleinJ LJL,
pubmed-author:PeckingAA,
pubmed-author:SerafiniA NAN,
pubmed-author:SubramanianRR,
pubmed-author:WolfeB LBL,
pubmed-author:WynantG EGE
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
41
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
953-62
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9715149-Adult,
pubmed-meshheading:9715149-Antibodies, Monoclonal,
pubmed-meshheading:9715149-Colorectal Neoplasms,
pubmed-meshheading:9715149-Female,
pubmed-meshheading:9715149-Humans,
pubmed-meshheading:9715149-Male,
pubmed-meshheading:9715149-Neoplasm Recurrence, Local,
pubmed-meshheading:9715149-Radioimmunodetection,
pubmed-meshheading:9715149-Safety,
pubmed-meshheading:9715149-Technetium,
pubmed-meshheading:9715149-Tomography, Emission-Computed, Single-Photon,
pubmed-meshheading:9715149-Whole-Body Counting
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Radioimmunoscintigraphy of recurrent, metastatic, or occult colorectal cancer with technetium Tc 99m 88BV59H21-2V67-66 (HumaSPECT-Tc), a totally human monoclonal antibody. Patient management benefit from a phase III multicenter study.
|
|
pubmed:affiliation |
Department of Colorectal and General Surgery, Mayo Clinic, Rochester, Minnesota, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
